---
title: "Polaryx Therapeutics, Inc. (PLYX) Receives a Buy from Maxim Group"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283719703.md"
description: "Polaryx Therapeutics, Inc. (PLYX) received a Buy rating from Maxim Group, as reported by analyst Jason McCarthy. The company's shares closed at USD 5.27, with an analyst consensus of Moderate Buy and a price target of $10.00. McCarthy, who covers the Healthcare sector, has an average return of -14.2% and a 32.73% success rate on his stock recommendations."
datetime: "2026-04-22T20:25:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283719703.md)
  - [en](https://longbridge.com/en/news/283719703.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283719703.md)
---

# Polaryx Therapeutics, Inc. (PLYX) Receives a Buy from Maxim Group

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Polaryx Therapeutics, Inc.. The company’s shares closed today at USD5.27.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

McCarthy covers the Healthcare sector, focusing on stocks such as Aprea Therapeutics, Moleculin Biotech, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of \-14.2% and a 32.73% success rate on recommended stocks.

Polaryx Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

### Related Stocks

- [PLYX.US](https://longbridge.com/en/quote/PLYX.US.md)
- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)
- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/286679543.md)
- [Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286678740.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md)
- [Lake Street Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/286569936.md)